These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 31695800)

  • 1. Theranostics in immuno-oncology using nanobody derivatives.
    Lecocq Q; De Vlaeminck Y; Hanssens H; D'Huyvetter M; Raes G; Goyvaerts C; Keyaerts M; Devoogdt N; Breckpot K
    Theranostics; 2019; 9(25):7772-7791. PubMed ID: 31695800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theranostic applications of antibodies in oncology.
    Fleuren ED; Versleijen-Jonkers YM; Heskamp S; van Herpen CM; Oyen WJ; van der Graaf WT; Boerman OC
    Mol Oncol; 2014 Jun; 8(4):799-812. PubMed ID: 24725480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies.
    Bannas P; Well L; Lenz A; Rissiek B; Haag F; Schmid J; Hochgräfe K; Trepel M; Adam G; Ittrich H; Koch-Nolte F
    Contrast Media Mol Imaging; 2014; 9(2):135-42. PubMed ID: 24523058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review).
    Yu S; Xiong G; Zhao S; Tang Y; Tang H; Wang K; Liu H; Lan K; Bi X; Duan S
    Int J Mol Med; 2021 Feb; 47(2):444-454. PubMed ID: 33416134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.
    Naidoo DB; Chuturgoon AA
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobody-based cancer therapy of solid tumors.
    Kijanka M; Dorresteijn B; Oliveira S; van Bergen en Henegouwen PM
    Nanomedicine (Lond); 2015 Jan; 10(1):161-74. PubMed ID: 25597775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostics - a sure cure for cancer after 100 years?
    Song Y; Zou J; Castellanos EA; Matsuura N; Ronald JA; Shuhendler A; Weber WA; Gilad AA; Müller C; Witney TH; Chen X
    Theranostics; 2024; 14(6):2464-2488. PubMed ID: 38646648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostics and metabolotheranostics for precision medicine in oncology.
    Bhujwalla ZM; Kakkad S; Chen Z; Jin J; Hapuarachchige S; Artemov D; Penet MF
    J Magn Reson; 2018 Jun; 291():141-151. PubMed ID: 29705040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
    Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
    Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.
    Wang J; Kang G; Yuan H; Cao X; Huang H; de Marco A
    Front Immunol; 2021; 12():838082. PubMed ID: 35116045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INDI-integrated nanobody database for immunoinformatics.
    Deszyński P; Młokosiewicz J; Volanakis A; Jaszczyszyn I; Castellana N; Bonissone S; Ganesan R; Krawczyk K
    Nucleic Acids Res; 2022 Jan; 50(D1):D1273-D1281. PubMed ID: 34747487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.
    D'Huyvetter M; Xavier C; Caveliers V; Lahoutte T; Muyldermans S; Devoogdt N
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1939-54. PubMed ID: 25035968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel immuno-gold labeling protocol for nanobody-based detection of HER2 in breast cancer cells using immuno-electron microscopy.
    Kijanka M; van Donselaar EG; Müller WH; Dorresteijn B; Popov-Čeleketić D; El Khattabi M; Verrips CT; van Bergen En Henegouwen PMP; Post JA
    J Struct Biol; 2017 Jul; 199(1):1-11. PubMed ID: 28552722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.
    Moradi A; Pourseif MM; Jafari B; Parvizpour S; Omidi Y
    Pharmacol Res; 2020 Jun; 156():104790. PubMed ID: 32278043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Versatile Nanosystem-Based Cancer Theranostics: Design Inspiration and Predetermined Routing.
    Opoku-Damoah Y; Wang R; Zhou J; Ding Y
    Theranostics; 2016; 6(7):986-1003. PubMed ID: 27217832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?
    Lütje S; Feldmann G; Essler M; Brossart P; Bundschuh RA
    J Nucl Med; 2020 Aug; 61(8):1137-1144. PubMed ID: 31924724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobodies-Useful Tools for Allergy Treatment?
    Flicker S; Zettl I; Tillib SV
    Front Immunol; 2020; 11():576255. PubMed ID: 33117377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle Diagnostics and Theranostics in the Clinic.
    Pallares RM; Mottaghy FM; Schulz V; Kiessling F; Lammers T
    J Nucl Med; 2022 Dec; 63(12):1802-1808. PubMed ID: 36302654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
    Paliard X; Rixe O
    Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.